Vernalis Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Winersh Wokingham United Kingdom (2003)
Status: Acquired by HitGen Inc. (2020)

Organization Overview

First Clinical Trial
2003
NCT00644033
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Vernalis (R&D) Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

frovatriptan (frova) (2 trials)

Drugs in Phase 2 Trials (6)

Key: Vernalis (3) Acquired (3)

entacapone (comtan) (1 trial)

indantadol (3 trials)

melevodopa (1 trial)

v10153 (1 trial)

v158866 (2 trials)

v81444 (3 trials)

Drugs in Phase 1 Trials (1)

v24343 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 2)

Cough (Phase 2)

Diabetic Neuropathies (Phase 2)

Headache (Phase 3)

Hyperkinesis (Phase 2)

Migraine Disorders (Phase 3)

Neuralgia (Phase 2)

Parkinson Disease (Phase 2)

Spinal Cord Injuries (Phase 2)

Stroke (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 8